Maria Sjöstrand

Maria Sjöstrand

Auto-generated profile, based on publicly available information

Maria Sjöstrand

Department of Medicine, Center for Molecular Medicine, Karolinska Institutet Karolinska University Hospital Stockholm Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
AKAfroditi Katsarou
Afroditi Katsarou
MSMaria Sjöstrand
Maria Sjöstrand
JNJyoti Naik
Jyoti Naik
JMJorge Mansilla-Soto
Jorge Mansilla-Soto
DKDionysia Kefala
Dionysia Kefala
MTMaria Themeli
Maria Themeli
Combination of a CAR and a chimeric costimulatory receptor augments cytotoxicity and durability of T cells and elimination of antigen-low tumors.

7 November 2022 in EMBO Reports
Verified
Journal Article
Open access
WNWilliam A Nyberg
William A Nyberg
DVDiego A Velasquez‐Pulgarin
Diego A Velasquez‐Pulgarin
THTianlin He
Tianlin He
MSMaria Sjöstrand
Maria Sjöstrand
LPLucia Pellé
Lucia Pellé
AEAlexander Espinosa
Alexander Espinosa
Melanoma tumors are highly metastatic partly due to the ability of melanoma cells to transition between invasive and proliferative states. However, the mechanisms underlying this plasticity are still not fully understood. To identify new epigenetic regulators of melanoma plasticity, we combined data mining, tumor models, proximity proteomics, and CUT&RUN sequencing. We focus on the druggable family of bromodomain epigenetic readers and identify TRIM28 as a new regulator of melanoma plasticity. We find that TRIM28 promotes the expression of pro‐invasive genes and that TRIM28 controls the balance between invasiveness and growth of melanoma cells. We demonstrate that TRIM28 acts via the transcription factor JUNB that directly regulates the expression of pro‐invasive and pro‐growth genes. Mechanistically, TRIM28 controls the expression of JUNB by negatively regulating its transcriptional elongation by RNA polymerase II. In conclusion, our results demonstrate that a TRIM28–JUNB axis controls the balance between invasiveness and growth in melanoma tumors and suggest that the bromodomain protein TRIM28 could be targeted to reduce tumor spread.

20 September 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
WNWilliam A Nyberg
William A Nyberg
THTianlin He
Tianlin He
MSMaria Sjöstrand
Maria Sjöstrand
DVDiego A Velasquez-Pulgarin
Diego A Velasquez-Pulgarin
LPLucia Pellé
Lucia Pellé
AEAlexander Espinosa
Alexander Espinosa
The introduction of immune checkpoint blockade has revolutionized the treatment of metastatic melanoma 1 . However, 40-60% of patients with metastatic melanoma do not respond to immune checkpoint blockade, and a significant fraction of patients acquire resistance to treatment 2,3 . This resilience and aggressiveness of melanoma tumors is partly due to their ability to switch between invasive and proliferative states 4,5 . The transition between phenotypic states indicates that phenotype switching occurs through reversible epigenetic mechanisms rather than by acquisition of mutations 6,7 . Identifying the epigenetic mechanisms that underlie phenotype switching of melanoma cells could potentially lead to new therapeutic strategies. Here we report that the bromodomain protein TRIM28 (KAP1/TIF1β) regulates a JUNB dependent phenotypic switch in melanoma cells. Knockdown of TRIM28 in melanoma cells reduced the expression of pro-invasive YAP1 signature genes, and led to reduced invasiveness and lung colonization. In contrast, TRIM28 knockdown increased the expression of KRAS signature genes and promoted tumor growth. TRIM28 interacted with the transcriptional elongation factors CDK9 and HEXIM1, and negatively regulated the transcriptional elongation of JUNB by RNA polymerase II. Rescue experiments demonstrated that the effects of TRIM28 knockdown were directly mediated by JUNB. Mechanistically, JUNB played a pivotal role in phenotype switching by inhibiting the invasiveness of melanoma cells and increasing the growth of melanoma tumors. Our results contribute to the understanding of melanoma plasticity, and suggest that cancer drugs inhibiting the transcriptional elongation of RNA polymerase II should be carefully evaluated in melanoma to exclude the risk for increased metastasis.